Assessment of humoral and cell-mediated immunity against Bordetella pertussis in adolescent, adult, and senior subjects in Italy

Epidemiology and Infection

Volumn 136, Issue 11, 2008, Pages 1576-1584

  Gabutti, Giovanni ^a   Bergamini, M ^a   Bonanni, P ^b   Guido, M ^c   Fenoglio, D ^d   Giammanco, A ^e   Sindoni, L ^f   Zotti, C ^g   Boddi, V ^b   Bamfi, F ^h   Severini, R ^a   Bechini, A ^b   Boccalini, S ^b   Crovari, P ^d   Ditommaso, S ⁱ   Gentile, M ⁱ   Lanci, G ⁱ   Durando, P ⁱ   Sticchi, L ⁱ   Renzoni, A ⁱ   Fuliano, P ⁱ   Tripodi, G ⁱ   Cavallaro, A ⁱ   Pesavento, G ⁱ   Silei Secchini, T ⁱ   Innocenti, B ⁱ   Squeri, R ⁱ   La Fauci, V ⁱ   Calimeri, S ⁱ   Lo Giudice, D ⁱ   De Donno, A ⁱ   Quattrocchi, M ⁱ   Sanapo, F ⁱ   Pasanisi, G C ⁱ   Taormina, S ⁱ   Bonura, C ⁱ   Cala C ⁱ   Ferrera, A ^j   more..

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF SALENTO   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY OF PALERMO   (Italy)

^f UNIVERSITY OF MESSINA   (Italy)

^g UNIVERSITY OF TURIN   (Italy)

^h GSK   (Italy)

ⁱ CEBR Genoa ^*

^j Centro di Eccellenza per la Ricerca Biomedica CEBR   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; PERTUSSIS TOXIN; PERTUSSIS VACCINE;

ADOLESCENT; ADULT; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BORDETELLA PERTUSSIS; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEOGRAPHIC DISTRIBUTION; GROUPS BY AGE; HUMAN; HUMORAL IMMUNITY; ITALY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATHOGENESIS; PERTUSSIS; POPULATION RESEARCH; SCHOOL CHILD; SEX DIFFERENCE;

EID: 48949094587     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268807000192     Document Type: Article

References (45)

1. Mortimer Jr. EA. Pertussis. In: Evans AS, Brachman PS. Bacterial Infections of Humans, 3rd edn. New York and London: Plenum Medical Book Co., 1998, pp. 529-543.
2. Hewlett EL, Halperin SA. Serological correlates of immunity to Bordetella pertussis. Vaccine 1998; 16: 1899-1900.
3. Locht C, Antoine R, Jacob-Dubuisson F. Bordetella pertussis, molecular pathogenesis under multiple aspects. Current Opinion in Microbiology 2001; 4: 82-89.
4. Tamura M, et al. Subunit structure of islet-activating protein, pertussis toxin, in conformity with the A-B model. Biochemistry 1982; 21: 5516-5522.
5. Ladant D, Ullmann A. Bordetella pertussis adenylate cyclase: A toxin with multiple talents. Trends in Microbiology 1999; 7 172-176.
6. Robbins JB, Pittman M. Bordetella. In: Davis BD, Dulbecco R, Eisen HN, Ginsberg HS, eds. Microbiologia. Quarta ed. Zanichelli, 1998, pp. 638-641.
7. Cookson BT, et al. Biological activities and chemical composition of purified tracheal cytotoxin of Bordetella pertussis. Infection and Immunity 1989; 57: 2223-2229.
8. Mills KHG. Immunity to Bordetella pertussis. Microbes and Infection 2001; 3: 655-677.
9. Campins-Martì M, et al. Recommendations are needed for adolescent and adult pertussis immunisation: Rationale and strategies for consideration. Vaccine 2001; 20: 641-646.
10. Wirsing von Konig CH, Halperin S, Riffelmann M, Guiso N. Pertussis of adults and infants. Lancet Infectious Diseases 2002; 2: 744-750.
11. Nelson JD. The changing epidemiology of pertussis in young infants. The role of adults as reservoirs of infection. American Journal of Diseases of Children 1978; 132: 371-373.
12. Mink CA, Sirota NM, Nugent S. Outbreak of pertussis in a fully immunized adolescent and adult population. Archives of Pediatrics & Adolescent Medicine 1994; 148: 153-157.
13. Wirsing von Konig CH, et al. Pertussis in adults: Frequency of transmission after household exposure. Lancet 1995; 346: 1326-1329. [Erratum in Lancet 1995; 346: 1502].
14. Senzilet LD, et al. Sentinel Health Unit Surveillance System Pertussis Working Group. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clinical Infectious Diseases 2001; 32: 1691-1697.
15. Pastore Celentano L, et al., on behalf of the EUVACNET Group Resurgence of pertussis in Europe. Pediatric Infectious Disease Journal 2005; 24: 761-765.
16. Edelman K, et al. Immunity to pertussis 5 years after booster immunization during adolescence. Clinical Infectious Diseases 2007; 44: 1271-1277.
17. Preston A. Bordetella pertussis: The intersection of genomics and pathobiology. Canadian Medical Association Journal 2005; 173 55-62.
18. Storsaeter J, et al. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998; 16: 1907-1916.
19. Cherry JD, et al. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998; 16: 1901-1906.
20. Olin P, et al. How to make sense of pertussis immunogenicity data. Clinical Infectious Diseases 2001; 33: S288-S291.
21. Rota MC, et al. Prevalence of markers of exposure to Bordetella pertussis among Italian young adults. Clinical Infectious Diseases 1998; 26: 297-302.
22. Tran Minh NN, et al. Cell-mediated immune responses to antigens of Bordetella pertussis and protection against pertussis in school children. Pediatric Infectious Disease Journal 1999; 18: 366-370.
23. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clinical Microbiology Reviews 2005; 18: 326-382.
24. Giammanco A, et al. European Seroepidemiology Network: standardisation of the assay results for pertussis. Vaccine 2003; 22: 112-120.
25. Pebody RG, et al. The seroepidemiology of Bordetella pertussis infection in Western Europe. Epidemiology and Infection 2005; 133: 159-171.
26. Zuercher AW, et al. Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine. Clinical and Experimental Immunology 2005; 143: 132-138.
27. Disis ML, et al. Maximizing the retention of antigen speci.c lymphocyte function after cryopreservation. Journal of Immunological Methods 2006; 308: 13-18.
28. Binkin NJ, et al. Epidemiology of pertussis in a developed country with low vaccination coverage: The Italian experience. Pediatric Infectious Disease Journal 1992; 11: 653-661.
29. Ciofi degli Atti ML, et al. Do changes in policy affect vaccine coverage levels? Results of a national study to evaluate childhood vaccination coverage and reasons for missed vaccination in Italy. Vaccine 2004; 22: 4351-4357.
30. Rota MC, et al. How increased pertussis vaccination coverage is changing the epidemiology of pertussis in Italy. Vaccine 2005; 23: 5299-5305.
31. Purdy KW, et al. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: A cost-benefit analysis. Clinical Infectious Diseases 2004; 39: 20-28.
32. Cherry JD. The epidemiology of pertussis: A comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics 2005; 115: 1422-1427.
33. Le T, et al. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: The APERT study. Journal of Infectious Diseases 2004; 190: 535-544.
34. Giammanco A, et al. Seroepidemiology of pertussis in Italy. Reviews of Infectious Diseases 1991; 13: 1216-1220.
35. De Melker H, et al. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. Journal of Clinical Microbiology 2000; 38: 800-806.
36. Polyzou A, et al. Seroepidemiology of Bordetella pertussis immune responses in a healthy population in Northern Greece. Journal of Clinical Laboratory Analysis 2004; 18: 211-214.
37. Nardone A, et al. Sero-epidemiology of Bordetella pertussis in England and Wales. Vaccine 2004; 22: 1314-1319.
38. Mills KHG, et al. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infection and Immunity 1998; 66 594-602.
39. Leef M, et al. Protective immunity to Bordetella pertussis requires both B cells and CD4+ T cells for key functions other than specific antibody production. Journal of Experimental Medicine 2000; 191: 1841-1852.
40. Edelman KJ, et al. Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine. Clinical Infectious Diseases 2004; 29: 179-185.
41. Forsyth KD, et al. New pertussis vaccination strategies beyond infancy: Recommendations by the Global Pertussis Initiative. Clinical Infectious Diseases 2004; 39: 1802-1809.
42. American Academy of Pediatrics. Committee on Infectious Diseases. Prevention of pertussis among adolescent: Recommendations for use of Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine. Pediatrics. Published online 28 December 2005. doi:10.1542/peds.2005-3038.
43. American Academy of Pediatrics. Committee on Infectious Diseases. Recommended childhood and adolescent immunization schedule - United States, 2006. Pediatrics 2006; 117: 239-240.
44. Bamberger ES, et al. What is new in pertussis? European Journal of Pediatrics. Published online: 1 August 2007. doi:10.1007/S00431-007-0548-2.
45. State Regional Conference. Agreement between the central Government, Regions and Autonomous Provinces of Trento and Bolzano regarding the New National Vaccine Plan 2005-2007. Determination 3 March 2005 in conformity with the fourth paragraph of Decree no. 281, 28 August 1997. Official Bulletin (Gazzetta Ufficiale), no. 86, 14 April 2005, Ordinary Supplement no. 63.